Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7323
    +0.0002 (+0.03%)
     

  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    91,175.96
    -489.30 (-0.53%)
     

  • CMC Crypto 200

    1,435.37
    +20.61 (+1.46%)
     

  • GOLD FUTURES

    2,334.90
    -7.20 (-0.31%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0520 (-1.12%)
     

  • NASDAQ futures

    17,717.50
    +110.75 (+0.63%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,246.64
    +694.48 (+1.85%)
     

  • CAD/EUR

    0.6834
    -0.0002 (-0.03%)
     

Editas: 4Q Earnings Snapshot

Associated Press
Updated ·1 min read

CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Thursday reported a loss of $62.5 million in its fourth quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1 per share.

The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 82 cents per share.

The genome editing company posted revenue of $11.4 million in the period, which beat Street forecasts. Four analysts surveyed by Zacks expected $6.8 million.

For the year, the company reported that its loss narrowed to $116 million, or $1.98 per share. Revenue was reported as $90.7 million.

ADVERTISEMENT

Editas shares have dropped 30% since the beginning of the year. The stock has more than doubled in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT